Attention-deficit/hyperactivity disorder: Are we medicating for social disadvantage? (For)

Journal of Paediatrics and Child Health

Volumn 42, Issue 9, 2006, Pages 544-547

  Isaacs, David ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Aboriginal; Community; Dexamphetamine; Methylphenidate; Stimulant

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ABDOMINAL PAIN; ABORIGINE; ANOREXIA; ATTENTION DEFICIT DISORDER; AUSTRALIA; CHILD PSYCHIATRY; DEPRESSION; FAMILY; HEADACHE; HEALTH CARE ACCESS; HUMAN; IRRITABILITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOCIAL DISCRIMINATION; TIC; WEIGHT REDUCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUSTRALIA; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD PSYCHOLOGY; HUMANS; OCEANIC ANCESTRY GROUP; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; SOCIOECONOMIC FACTORS; VULNERABLE POPULATIONS;

EID: 33747389345     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2006.00919.x     Document Type: Review

References (26)

1. Efron D, Oberklaid F. Psychotropic medication for children: the paediatrician's dilemma. J. Paediatr. Child Health 2003; 39: 509-10.
2. Rey JM, Sawyer MG. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders? Br. J. Psychiatry. 2003; 182: 284-6.
3. Jensen PS, Kettle L, Roper MT et al. Are stimulants over-prescribed? Treatment of ADHD in four US communities. J. Am. Acad. Child Adolesc. Psychiatry 1999; 38: 797-804.
4. Coghill D, Markovitch H. Use of stimulants for attention deficit hyperactivity disorder. BMJ 2004; 329: 908-9.
5. Isaacs D, Fitzgerald D. Stimulants for paediatricians. Arch. Dis. Child 2005; 90: 1251-2.
6. Hewson PH, Anderson PK, Dinning AH et al. A 12 month profile of community paediatric consultations in the Barwon region. J. Paediatr. Child Health 1999; 35: 16-22.
7. Gunesekera H, Buckmaster A. Training in general paediatrics: is it time for change? J. Paediatr. Child Health 2004; 40: 510-16.
8. Hickie IB, Groom GL, McGorry PD, Davenport TA, Luscombe GM. Australian mental health reform: time for real outcomes. Med. J. Aust. 2005; 182: 401-6.
9. Graetz BW, Sawyer MG, Hazell PL, Arney F, Baghurst P. Validity of DSMIV ADHD subtypes in a nationally representative sample of Australian children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2001; 40: 1410-17.
10. Counts CA, Nigg GT, Stawicki JA, Rappley MD, von Eye A. Family adversity in DSM-IV ADHD combined and inattentive subtypes and associated disruptive behaviour problems. J. Am. Acad. Child Adolesc. Psychiatry 2005; 44: 690-8.
11. Greenhill LL, Pliszka S, Dulcan MK et al. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J. Am. Acad. Child Adolesc. Psychiatry 2002; 41: 26S-49S.
12. Hill P, Taylor B. An auditable protocol for treating attention deficit hyperactivity disorder. Arch. Dis. Child 2001; 84: 404-9.
13. National Health and Medical Research Council. Attention Deficit Hyperactivity Disorder. Canberra: Commonwealth of Australia, 1997.
14. Angold A, Erkanli A, Egger HL et al. Stimulant treatment for children: a community perspective. J. Am. Acad. Child Adolesc. Psychiatry 2000; 39: 975-84.
15. Nolan EE, Gadow KD, Sprafkin J. Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren. J. Am. Acad. Child Adolesc. Psychiatry 2001; 40: 241-9.
16. Pineda D, Ardila A, Roisselli M et al. Prevalence of attention-deficit/ hyperactivity disorder symptoms in 4- to 17-year old children in the general population. J. Abnorm. Child Psychol. 1999; 27: 455-62.
17. Kozlowska K, Harmey L. Maltreated children: a systems approach to treatment planning in clinical settings. Aust. N. Z. J. Fam. Ther. 2003; 24: 75-87.
18. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol. Drug Safety 2001; 10: 85-94.
19. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety and practicality of treatments for adolescents with attention deficit/hyperactivity disorder. Clin. Child Fam. Psychol. Rev. 2000; 3: 243-67.
20. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment of children with ADHD. Arch. Gen. Psychiatry 1999; 56: 1073-86.
21. Duff G. Message from Professor G Duff, Chairman, Committee on Safety of Medicines. 2005 Available from: http://www.mhra.gov.uk/home/groups/pl-p/ documents/drugsafetymessage/con2018039.pdf [accessed 28 November 2005].
22. Berbatis CG, Sunderland VB, Bulsara M. Licit psychostimulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med. J. Aust. 2002; 177: 539-43.
23. Reid R, Hakendorf P, Prosser B. Use of psychostimulant medication for ADHD in South Australia. J. Am. Acad. Child Adolesc. Psychiatry 2002; 41: 906-13.
24. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. Med. J. Aust. 2002; 177: 21-5.
25. Bjornstad G, Montgomery P. Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents. Cochrane Database Syst. Rev. 2005; 3.
26. Abikoff H, Hechtman L, Klein RG et al. Symptomatic improvement in children with ADHD treated with long-term methylohenidate and multimodal psychosocial treatment. J. Am. Acad. Child Adolesc. Psychiatry 2004; 43: 802-11.